Autophagy regulates fatty acid availability for oxidative phosphorylation through mitochondria-endoplasmic reticulum contact sites.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
13 08 2020
Historique:
received: 13 06 2019
accepted: 22 07 2020
entrez: 15 8 2020
pubmed: 15 8 2020
medline: 9 9 2020
Statut: epublish

Résumé

Autophagy has been associated with oncogenesis with one of its emerging key functions being its contribution to the metabolism of tumors. Therefore, deciphering the mechanisms of how autophagy supports tumor cell metabolism is essential. Here, we demonstrate that the inhibition of autophagy induces an accumulation of lipid droplets (LD) due to a decrease in fatty acid β-oxidation, that leads to a reduction of oxidative phosphorylation (OxPHOS) in acute myeloid leukemia (AML), but not in normal cells. Thus, the autophagic process participates in lipid catabolism that supports OxPHOS in AML cells. Interestingly, the inhibition of OxPHOS leads to LD accumulation with the concomitant inhibition of autophagy. Mechanistically, we show that the disruption of mitochondria-endoplasmic reticulum (ER) contact sites (MERCs) phenocopies OxPHOS inhibition. Altogether, our data establish that mitochondria, through the regulation of MERCs, controls autophagy that, in turn finely tunes lipid degradation to fuel OxPHOS supporting proliferation and growth in leukemia.

Identifiants

pubmed: 32792483
doi: 10.1038/s41467-020-17882-2
pii: 10.1038/s41467-020-17882-2
pmc: PMC7426880
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4056

Références

Klionsky, D. J. Autophagy: from phenomenology to molecular understanding in less than a decade. Nat. Rev. Mol. Cell Biol.8, 931–937 (2007).
doi: 10.1038/nrm2245 pubmed: 17712358
Moreau, K., Luo, S. & Rubinsztein, D. C. Cytoprotective roles for autophagy. Curr. Opin. Cell Biol.22, 206–211 (2010).
pubmed: 20045304 pmcid: 2860226 doi: 10.1016/j.ceb.2009.12.002
Kuma, A. et al. The role of autophagy during the early neonatal starvation period. Nature432, 1032–1036 (2004).
pubmed: 15525940 doi: 10.1038/nature03029
Karsli-Uzunbas, G. et al. Autophagy is required for glucose homeostasis and lung tumor maintenance. Cancer Discov.4, 914–927 (2014).
pubmed: 24875857 pmcid: 4125614 doi: 10.1158/2159-8290.CD-14-0363
Guo, J. Y. et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev.25, 460–470 (2011).
pubmed: 21317241 pmcid: 3049287 doi: 10.1101/gad.2016311
Heydt, Q. et al. Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia. Oncogene37, 787–797 (2018).
pubmed: 29059168 doi: 10.1038/onc.2017.376
Lock, R. et al. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. Mol. Biol. Cell22, 165–178 (2011).
pubmed: 21119005 pmcid: 3020913 doi: 10.1091/mbc.e10-06-0500
Karvela, M. et al. ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells. Autophagy12, 936–948 (2016).
pubmed: 27168493 pmcid: 4922442 doi: 10.1080/15548627.2016.1162359
Sousa, C. M. et al. Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature536, 479–483 (2016).
pubmed: 27509858 pmcid: 5228623 doi: 10.1038/nature19084
Katheder, N. S. et al. Microenvironmental autophagy promotes tumour growth. Nature541, 417–420 (2017).
pubmed: 28077876 pmcid: 5612666 doi: 10.1038/nature20815
Kimmelman, A. C. & White, E. Autophagy and tumor metabolism. Cell Metab.25, 1037–1043 (2017).
pubmed: 28467923 pmcid: 5604466 doi: 10.1016/j.cmet.2017.04.004
Yang, S. et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev.25, 717–729 (2011).
pubmed: 21406549 pmcid: 3070934 doi: 10.1101/gad.2016111
Guo, J. Y. et al. Autophagy provides metabolic substrates to maintain energy charge and nucleotide pools in Ras-driven lung cancer cells. Genes Dev.30, 1704–1717 (2016).
pubmed: 27516533 pmcid: 5002976 doi: 10.1101/gad.283416.116
Strohecker, A. M. et al. Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. Cancer Discov.3, 1272–1285 (2013).
pubmed: 23965987 doi: 10.1158/2159-8290.CD-13-0397
Weinberg, F. et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl Acad. Sci. USA107, 8788–8793 (2010).
pubmed: 20421486 doi: 10.1073/pnas.1003428107 pmcid: 2889315
Ricciardi, M. R. et al. Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias. Blood126, 1925–1929 (2015).
doi: 10.1182/blood-2014-12-617498 pubmed: 26276667
Samudio, I. et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J. Clin. Invest.120, 142–156 (2010).
pubmed: 20038799 doi: 10.1172/JCI38942
Farge, T. et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov.7, 716–735 (2017).
pubmed: 28416471 pmcid: 5501738 doi: 10.1158/2159-8290.CD-16-0441
Scotland, S. et al. Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells. Leukemia27, 2129–2138 (2013).
pubmed: 23568147 doi: 10.1038/leu.2013.107
Skrtić, M. et al. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell20, 674–688 (2011).
pubmed: 22094260 pmcid: 3221282 doi: 10.1016/j.ccr.2011.10.015
Baccelli, I. et al. Mubritinib targets the electron transport chain complex I and reveals the landscape of OXPHOS dependency in acute myeloid leukemia. Cancer Cell36, 84–99 (2019).
pubmed: 31287994 doi: 10.1016/j.ccell.2019.06.003
Pardee, T. S. et al. A Phase I study of CPI-613 in combination with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia. Clin. Cancer Res.24, 2060–2073 (2018).
pubmed: 29437791 pmcid: 5932089 doi: 10.1158/1078-0432.CCR-17-2282
Larrue, C. et al. Oncogenic KIT mutations induce STAT3-dependent autophagy to support cell proliferation in acute myeloid leukemia. Oncogenesis8, 39 (2019).
pubmed: 31311917 pmcid: 6635375 doi: 10.1038/s41389-019-0148-9
Janikiewicz, J. et al. Mitochondria-associated membranes in aging and senescence: structure, function, and dynamics. Cell Death Dis.9, 332 (2018).
pubmed: 29491385 pmcid: 5832430 doi: 10.1038/s41419-017-0105-5
Singh, R. et al. Autophagy regulates lipid metabolism. Nature458, 1131–1135 (2009).
pubmed: 19339967 pmcid: 2676208 doi: 10.1038/nature07976
Weidberg, H., Shvets, E. & Elazar, Z. Lipophagy: selective catabolism designed for lipids. Dev. Cell16, 628–630 (2009).
pubmed: 19460339 doi: 10.1016/j.devcel.2009.05.001
Guo, J. Y. et al. Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev.27, 1447–1461 (2013).
pubmed: 23824538 pmcid: 3713426 doi: 10.1101/gad.219642.113
Viale, A. et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature514, 628–632 (2014).
pubmed: 25119024 pmcid: 4376130 doi: 10.1038/nature13611
Loubière, C. et al. Metformin-induced energy deficiency leads to the inhibition of lipogenesis in prostate cancer cells. Oncotarget6, 15652–15661 (2015).
pubmed: 26002551 pmcid: 4558177 doi: 10.18632/oncotarget.3404
Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy12, 1–222 (2016).
pubmed: 26799652 pmcid: 4835977 doi: 10.1080/15548627.2015.1100356
Giacomello, M. & Pellegrini, L. The coming of age of the mitochondria-ER contact: a matter of thickness. Cell Death Differ.23, 1417–1427 (2016).
pubmed: 27341186 pmcid: 5072433 doi: 10.1038/cdd.2016.52
Carreras-Sureda, A. et al. Non-canonical function of IRE1α determines mitochondria-associated endoplasmic reticulum composition to control calcium transfer and bioenergetics. Nat. Cell Biol.21, 755–767 (2019).
pubmed: 31110288 pmcid: 7246037 doi: 10.1038/s41556-019-0329-y
Sassano, M. L., Vliet, V. R. A. & Agostinis, P. Mitochondria-associated membranes as networking platforms and regulators of cancer cell fate. Front. Oncol. 7, 174 (2017).
pubmed: 28868254 pmcid: 5563315 doi: 10.3389/fonc.2017.00174
Hamasaki, M. et al. Autophagosomes form at ER-mitochondria contact sites. Nature495, 389–393 (2013).
pubmed: 23455425 doi: 10.1038/nature11910
Garofalo, T. et al. Evidence for the involvement of lipid rafts localized at the ER-mitochondria associated membranes in autophagosome formation. Autophagy12, 917–935 (2016).
pubmed: 27123544 pmcid: 4922444 doi: 10.1080/15548627.2016.1160971
Wieckowski, M. R., Giorgi, C., Lebiedzinska, M., Duszynski, J. & Pinton, P. Isolation of mitochondria-associated membranes and mitochondria from animal tissues and cells. Nat. Protoc.4, 1582–1590 (2009).
pubmed: 19816421 doi: 10.1038/nprot.2009.151
Tubbs, E. et al. Mitochondria-associated endoplasmic reticulum membrane (MAM) integrity is required for insulin signaling and is implicated in hepatic insulin resistance. Diabetes63, 3279–3294 (2014).
pubmed: 24947355 doi: 10.2337/db13-1751
de Brito, O. M. & Scorrano, L. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature456, 605–610 (2008).
pubmed: 19052620 doi: 10.1038/nature07534
Csordás, G. et al. Structural and functional features and significance of the physical linkage between ER and mitochondria. J. Cell Biol.174, 915–921 (2006).
pubmed: 16982799 pmcid: 2064383 doi: 10.1083/jcb.200604016
Molina, J. R. et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat. Med.24, 1036–1046 (2018).
pubmed: 29892070 doi: 10.1038/s41591-018-0052-4
Sui, X. et al. Metformin: a novel but controversial drug in cancer prevention and treatment. Mol. Pharm.12, 3783–3791 (2015).
pubmed: 26430787 doi: 10.1021/acs.molpharmaceut.5b00577
Viollet, B. et al. Targeting the AMPK pathway for the treatment of type 2 diabetes. Front. Biosci. Landmark Ed.14, 3380–3400 (2009).
pubmed: 19273282 pmcid: 2677695 doi: 10.2741/3460
Ma, X. et al. Mitochondrial electron transport chain complex III is required for antimycin A to inhibit autophagy. Chem. Biol.18, 1474–1481 (2011).
pubmed: 22118681 pmcid: 3225892 doi: 10.1016/j.chembiol.2011.08.009
Thomas, H. E. et al. Mitochondrial complex i activity is required for maximal autophagy. Cell Rep.24, 2404–2417.e8 (2018).
pubmed: 30157433 pmcid: 6298213 doi: 10.1016/j.celrep.2018.07.101
Zang, M. et al. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J. Biol. Chem.279, 47898–47905 (2004).
pubmed: 15371448 doi: 10.1074/jbc.M408149200
Foretz, M., Guigas, B., Bertrand, L., Pollak, M. & Viollet, B. Metformin: from mechanisms of action to therapies. Cell Metab.20, 953–966 (2014).
pubmed: 25456737 doi: 10.1016/j.cmet.2014.09.018
Hailey, D. W. et al. Mitochondria supply membranes for autophagosome biogenesis during starvation. Cell141, 656–667 (2010).
pubmed: 20478256 pmcid: 3059894 doi: 10.1016/j.cell.2010.04.009
Bosc, C., Selak, M. A. & Sarry, J.-E. Resistance is futile: targeting mitochondrial energetics and metabolism to overcome drug resistance in cancer treatment. Cell Metab.26, 705–707 (2017).
pubmed: 29117545 doi: 10.1016/j.cmet.2017.10.013
Carracedo, A., Cantley, L. C. & Pandolfi, P. P. Cancer metabolism: fatty acid oxidation in the limelight. Nat. Rev. Cancer13, 227–232 (2013).
pubmed: 23446547 pmcid: 3766957 doi: 10.1038/nrc3483
Sawyer, B. T. et al. Targeting fatty acid oxidation to promote anoikis and inhibit ovarian cancer progression. Mol. Cancer Res. MCR18, 1088–1098 (2020).
pubmed: 32198139 doi: 10.1158/1541-7786.MCR-19-1057
Pascual, G. et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature541, 41–45 (2017).
pubmed: 27974793 doi: 10.1038/nature20791
Lee, C.-K. et al. Tumor metastasis to lymph nodes requires YAP-dependent metabolic adaptation. Science363, 644–649 (2019).
pubmed: 30733421 doi: 10.1126/science.aav0173
Vazquez, F. et al. PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell23, 287–301 (2013).
pubmed: 23416000 pmcid: 3708305 doi: 10.1016/j.ccr.2012.11.020
Camarda, R. et al. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat. Med.22, 427–432 (2016).
pubmed: 26950360 pmcid: 4892846 doi: 10.1038/nm.4055
Le Marchand-Brustel, Y., Gautier, N., Cormont, M. & Van Obberghen, E. Wortmannin inhibits the action of insulin but not that of okadaic acid in skeletal muscle: comparison with fat cells. Endocrinology136, 3564–3570 (1995).
pubmed: 7628394 doi: 10.1210/endo.136.8.7628394
Regazzetti, C. et al. Regulated in development and DNA damage responses -1 (REDD1) protein contributes to insulin signaling pathway in adipocytes. PloS ONE7, e52154 (2012).
pubmed: 23272222 pmcid: 3525563 doi: 10.1371/journal.pone.0052154
Stuani, L. et al. Stable isotope labeling highlights enhanced fatty acid and lipid metabolism in human acute myeloid leukemia. Int. J. Mol. Sci. 19, 3325 (2018).

Auteurs

Claudie Bosc (C)

Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.
Equipe labellisée, La Ligue contre le Cancer, Toulouse, France.

Nicolas Broin (N)

Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.
Equipe labellisée, La Ligue contre le Cancer, Toulouse, France.

Marjorie Fanjul (M)

Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.
Equipe labellisée, La Ligue contre le Cancer, Toulouse, France.

Estelle Saland (E)

Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.
Equipe labellisée, La Ligue contre le Cancer, Toulouse, France.

Thomas Farge (T)

Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.
Equipe labellisée, La Ligue contre le Cancer, Toulouse, France.

Charly Courdy (C)

Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.
Equipe labellisée, La Ligue contre le Cancer, Toulouse, France.

Aurélie Batut (A)

MetaToul-MetaboHUB, National Infrastructure of Metabolomics and Fluxomics, Toulouse, F-31077, France.

Rawand Masoud (R)

Aix Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, Marseille, France.

Clément Larrue (C)

Translational Research Centre in Onco-hematology, Faculty of Medicine, University of Geneva, 1211, Geneva, Switzerland.

Sarah Skuli (S)

Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.
Equipe labellisée, La Ligue contre le Cancer, Toulouse, France.
Division of Hematology and Oncology, Hospital of The University of Pennsylvania, Philadelphia, PA, USA.

Nicolas Espagnolle (N)

STROMALab, Université de Toulouse, CNRS ERL5311, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France.

Jean-Christophe Pagès (JC)

STROMALab, Université de Toulouse, CNRS ERL5311, EFS, INP-ENVT, Inserm U1031, UPS, Toulouse, France.

Alice Carrier (A)

Aix Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, Marseille, France.

Frédéric Bost (F)

Inserm U1065, C3M, Team Cellular and Molecular Physiopathology of Obesity and Diabetes, Université Nice Côte d'Azur, Inserm, Nice, France.

Justine Bertrand-Michel (J)

MetaToul-MetaboHUB, National Infrastructure of Metabolomics and Fluxomics, Toulouse, F-31077, France.

Jérôme Tamburini (J)

Translational Research Centre in Onco-hematology, Faculty of Medicine, University of Geneva, 1211, Geneva, Switzerland.
Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, F-75014, Paris, France.

Christian Récher (C)

Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.
Equipe labellisée, La Ligue contre le Cancer, Toulouse, France.
Service d'hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.

Sarah Bertoli (S)

Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.
Equipe labellisée, La Ligue contre le Cancer, Toulouse, France.
Service d'hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.

Véronique Mansat-De Mas (V)

Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.
Equipe labellisée, La Ligue contre le Cancer, Toulouse, France.
Laboratoire d'Hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.

Stéphane Manenti (S)

Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France.
Equipe labellisée, La Ligue contre le Cancer, Toulouse, France.

Jean-Emmanuel Sarry (JE)

Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France. jean-emmanuel.sarry@inserm.fr.
Equipe labellisée, La Ligue contre le Cancer, Toulouse, France. jean-emmanuel.sarry@inserm.fr.

Carine Joffre (C)

Cancer Research Center of Toulouse (CRCT), INSERM U1037, CNRS ERL5294, University of Toulouse, Toulouse, France. carine.joffre@inserm.fr.
Equipe labellisée, La Ligue contre le Cancer, Toulouse, France. carine.joffre@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH